The Experts below are selected from a list of 135 Experts worldwide ranked by ideXlab platform

Joyce H. S. You - One of the best experts on this subject based on the ideXlab platform.

  • Potential Cost-Effectiveness of an Influenza Vaccination Program Offering Microneedle Patch for Vaccine Delivery in Children
    PloS one, 2016
    Co-Authors: Carlos Wong, Minghuan Jiang, Joyce H. S. You
    Abstract:

    Objective The influenza vaccine coverage rate of children is low in Hong Kong. Microneedle patches (MNPs) is a technology under development for painless delivery of vaccines. This study aimed to examine the potential clinical outcomes and direct medical costs of an influenza Program Offering MNP vaccine to children who have declined intramuscular (IM) vaccine in Hong Kong. Methods A decision model was designed to compare potential outcomes between IM vaccine Program and a Program Offering MNP vaccine to those declined IM vaccine (IM/MNP Program) in a hypothetical cohort of children over one-year time horizon. The model outcomes included direct medical cost, influenza infection rate, mortality rate, and quality-adjusted life-years (QALYs) loss. Model inputs were retrieved from published literature. Sensitivity analyses were performed to examine the robustness of model results. Results In base-case analysis, IM/MNP Program was more costly per child (USD19.13 versus USD13.69; USD1 = HKD7.8) with lower influenza infection rate (98.9 versus 124.8 per 1,000 children), hospitalization rate (0.83 versus 1.05 per 1,000 children) and influenza-related mortality rate (0.00042 versus 0.00052 per 1,000 children) when compared to IM Program. The incremental cost per QALY saved (ICER) of IM/MNP Program versus IM Program was 27,200 USD/QALY. Using gross domestic product (GDP) per capita of Hong Kong (USD40,594) as threshold of willingness-to-pay (WTP) per QALY, one-way sensitivity analysis found ICER of IM/MNP to exceed WTP when duration of illness in outpatient setting was 1.39-time of IM vaccine cost. In 10,000 Monte Carlo simulations, IM/MNP Program was the preferred option in 57.28% and 91.68% of the time, using 1x and 3x GDP per capita as WTP threshold, respectively. Conclusion Acceptance of IM/MNP Program as the preferred Program was subject to the WTP threshold, duration of illness in outpatient settings, and cost of MNP vaccine.

  • Cost-effectiveness of an influenza vaccination Program Offering intramuscular and intradermal vaccines versus intramuscular vaccine alone for elderly.
    Vaccine, 2016
    Co-Authors: Man-kit Leung, Joyce H. S. You
    Abstract:

    Abstract Background Intradermal (ID) injection is an alternative route for influenza vaccine administration in elderly with potential improvement of vaccine coverage. This study aimed to investigate the cost-effectiveness of an influenza vaccination Program Offering ID vaccine to elderly who had declined intramuscular (IM) vaccine from the perspective of Hong Kong public healthcare provider. Methods A decision analytic model was used to simulate outcomes of two Programs: IM vaccine alone (IM Program), and IM or ID vaccine (IM/ID Program) in a hypothetic cohort of elderly aged 65 years. Outcome measures included influenza-related direct medical cost, infection rate, mortality rate, quality-adjusted life years (QALYs) loss, and incremental cost per QALY saved (ICER). Model inputs were derived from literature. Sensitivity analyses evaluated the impact of uncertainty of model variables. Results In base-case analysis, the IM/ID Program was more costly (USD52.82 versus USD47.59 per individual to whom vaccine was offered) with lower influenza infection rate (8.71% versus 9.65%), mortality rate (0.021% versus 0.024%) and QALYs loss (0.00336 versus 0.00372) than the IM Program. ICER of IM/ID Program was USD14,528 per QALY saved. One-way sensitivity analysis found ICER of IM/ID Program to exceed willingness-to-pay threshold (USD39,933) when probability of influenza infection in unvaccinated elderly decreased from 10.6% to 5.4%. In 10,000 Monte Carlo simulations of elderly populations of Hong Kong, the IM/ID Program was the preferred option in 94.7% of time. Conclusions An influenza vaccination Program Offering ID vaccine to elderly who had declined IM vaccine appears to be a highly cost-effective option.

Man-kit Leung - One of the best experts on this subject based on the ideXlab platform.

  • Cost-effectiveness of an influenza vaccination Program Offering intramuscular and intradermal vaccines versus intramuscular vaccine alone for elderly.
    Vaccine, 2016
    Co-Authors: Man-kit Leung, Joyce H. S. You
    Abstract:

    Abstract Background Intradermal (ID) injection is an alternative route for influenza vaccine administration in elderly with potential improvement of vaccine coverage. This study aimed to investigate the cost-effectiveness of an influenza vaccination Program Offering ID vaccine to elderly who had declined intramuscular (IM) vaccine from the perspective of Hong Kong public healthcare provider. Methods A decision analytic model was used to simulate outcomes of two Programs: IM vaccine alone (IM Program), and IM or ID vaccine (IM/ID Program) in a hypothetic cohort of elderly aged 65 years. Outcome measures included influenza-related direct medical cost, infection rate, mortality rate, quality-adjusted life years (QALYs) loss, and incremental cost per QALY saved (ICER). Model inputs were derived from literature. Sensitivity analyses evaluated the impact of uncertainty of model variables. Results In base-case analysis, the IM/ID Program was more costly (USD52.82 versus USD47.59 per individual to whom vaccine was offered) with lower influenza infection rate (8.71% versus 9.65%), mortality rate (0.021% versus 0.024%) and QALYs loss (0.00336 versus 0.00372) than the IM Program. ICER of IM/ID Program was USD14,528 per QALY saved. One-way sensitivity analysis found ICER of IM/ID Program to exceed willingness-to-pay threshold (USD39,933) when probability of influenza infection in unvaccinated elderly decreased from 10.6% to 5.4%. In 10,000 Monte Carlo simulations of elderly populations of Hong Kong, the IM/ID Program was the preferred option in 94.7% of time. Conclusions An influenza vaccination Program Offering ID vaccine to elderly who had declined IM vaccine appears to be a highly cost-effective option.

Carlos Wong - One of the best experts on this subject based on the ideXlab platform.

  • Potential Cost-Effectiveness of an Influenza Vaccination Program Offering Microneedle Patch for Vaccine Delivery in Children
    PloS one, 2016
    Co-Authors: Carlos Wong, Minghuan Jiang, Joyce H. S. You
    Abstract:

    Objective The influenza vaccine coverage rate of children is low in Hong Kong. Microneedle patches (MNPs) is a technology under development for painless delivery of vaccines. This study aimed to examine the potential clinical outcomes and direct medical costs of an influenza Program Offering MNP vaccine to children who have declined intramuscular (IM) vaccine in Hong Kong. Methods A decision model was designed to compare potential outcomes between IM vaccine Program and a Program Offering MNP vaccine to those declined IM vaccine (IM/MNP Program) in a hypothetical cohort of children over one-year time horizon. The model outcomes included direct medical cost, influenza infection rate, mortality rate, and quality-adjusted life-years (QALYs) loss. Model inputs were retrieved from published literature. Sensitivity analyses were performed to examine the robustness of model results. Results In base-case analysis, IM/MNP Program was more costly per child (USD19.13 versus USD13.69; USD1 = HKD7.8) with lower influenza infection rate (98.9 versus 124.8 per 1,000 children), hospitalization rate (0.83 versus 1.05 per 1,000 children) and influenza-related mortality rate (0.00042 versus 0.00052 per 1,000 children) when compared to IM Program. The incremental cost per QALY saved (ICER) of IM/MNP Program versus IM Program was 27,200 USD/QALY. Using gross domestic product (GDP) per capita of Hong Kong (USD40,594) as threshold of willingness-to-pay (WTP) per QALY, one-way sensitivity analysis found ICER of IM/MNP to exceed WTP when duration of illness in outpatient setting was 1.39-time of IM vaccine cost. In 10,000 Monte Carlo simulations, IM/MNP Program was the preferred option in 57.28% and 91.68% of the time, using 1x and 3x GDP per capita as WTP threshold, respectively. Conclusion Acceptance of IM/MNP Program as the preferred Program was subject to the WTP threshold, duration of illness in outpatient settings, and cost of MNP vaccine.

Minghuan Jiang - One of the best experts on this subject based on the ideXlab platform.

  • Potential Cost-Effectiveness of an Influenza Vaccination Program Offering Microneedle Patch for Vaccine Delivery in Children
    PloS one, 2016
    Co-Authors: Carlos Wong, Minghuan Jiang, Joyce H. S. You
    Abstract:

    Objective The influenza vaccine coverage rate of children is low in Hong Kong. Microneedle patches (MNPs) is a technology under development for painless delivery of vaccines. This study aimed to examine the potential clinical outcomes and direct medical costs of an influenza Program Offering MNP vaccine to children who have declined intramuscular (IM) vaccine in Hong Kong. Methods A decision model was designed to compare potential outcomes between IM vaccine Program and a Program Offering MNP vaccine to those declined IM vaccine (IM/MNP Program) in a hypothetical cohort of children over one-year time horizon. The model outcomes included direct medical cost, influenza infection rate, mortality rate, and quality-adjusted life-years (QALYs) loss. Model inputs were retrieved from published literature. Sensitivity analyses were performed to examine the robustness of model results. Results In base-case analysis, IM/MNP Program was more costly per child (USD19.13 versus USD13.69; USD1 = HKD7.8) with lower influenza infection rate (98.9 versus 124.8 per 1,000 children), hospitalization rate (0.83 versus 1.05 per 1,000 children) and influenza-related mortality rate (0.00042 versus 0.00052 per 1,000 children) when compared to IM Program. The incremental cost per QALY saved (ICER) of IM/MNP Program versus IM Program was 27,200 USD/QALY. Using gross domestic product (GDP) per capita of Hong Kong (USD40,594) as threshold of willingness-to-pay (WTP) per QALY, one-way sensitivity analysis found ICER of IM/MNP to exceed WTP when duration of illness in outpatient setting was 1.39-time of IM vaccine cost. In 10,000 Monte Carlo simulations, IM/MNP Program was the preferred option in 57.28% and 91.68% of the time, using 1x and 3x GDP per capita as WTP threshold, respectively. Conclusion Acceptance of IM/MNP Program as the preferred Program was subject to the WTP threshold, duration of illness in outpatient settings, and cost of MNP vaccine.

John A Schneider - One of the best experts on this subject based on the ideXlab platform.

  • corrigendum to 2269 hiv positive individuals who report being in care are less likely to be co infected with an sti an analysis of network testing a service Program Offering hiv and sti testing services to individual at risk for hiv
    Open Forum Infectious Diseases, 2018
    Co-Authors: Rodal Issema, Tamika Songster, Mallory Edgar, Billy Davis, Tabatha Lee, James Harris, Takisha Cleveland, Henry Chancler, Julia C Rosebush, John A Schneider
    Abstract:

    BACKGROUND The prevalence of STIs among people living with HIV (PLWH) has implications for HIV treatment as prevention and community efforts to stop the spread of HIV. We explored the factors associated with HIV/STI co-infection in HIV-positive individuals. METHODS We analyzed data from our "Network Testing" service Program, which was designed to expand HIV/STI testing services to high-risk individuals including gay, bisexual, and other men who have sex with men (MSM) in Chicago's South side, a high HIV prevalent area. This Program provides incentivized testing to participants and up to six referred individuals within their social network. The prevalence of selected STIs, including syphilis, gonorrhea, or chlamydia infection, among HIV-positive individuals was evaluated. Bivariate and multivariable logistic regression analyses were used to assess sociodemographic, testing history, and risk factors significantly associated with HIV/STI co-infection. RESULTS Of the 295 HIV-positive individuals, 110 (37%) tested positive for at least one STI, with 90 (32%) testing positive for syphilis, 23 (16%) for gonorrhea, and 12 (8%) for chlamydia. The median age was 27 years old and 91% of clients were MSM. In multivariable analyses, individuals who reported being in care were less likely to be co-infected (adjusted odds ratio [aOR] 0.45, 95% confidence interval 0.23-0.90). Additionally, participants who reported having a previous STI test were more likely to be co-infected (aOR=6.10, 95% CI: 1.87-19.90). We found no association with co-infection and other risk factors including multiple partners and condomless sex. CONCLUSION The high STI prevalence among HIV-positive individuals suggests: 1) a continued need for regular STI testing and treatment among PLWH to reduce the likelihood of HIV transmission to others; and 2) the receipt of HIV care serves as an important opportunity to provide comprehensive services including STI testing/treatment. DISCLOSURES R. Issema, CDC FOA PS15-1502: Employee of Grant Recipient and Employee, Grant recipient. CDC FOA PS17-1704: Employee of Grant Recipient, Grant recipient. T. Songster, CDC FOA 15-1502: Employee of the grant recipient, Grant recipient. CDC FOA 17-1704: Employee of grant recipient, Grant recipient. M. Edgar, CDC FOA PS15-1502: Employee of Grant Recipient, Grant recipient. B. Davis, CDC FOA PS15-1502: Employee of Grant Recipient, Grant recipient. T. Lee, CDC FOA PS15-1502: Employee of Grant Recipient, Grant recipient. J. Harris, CDC FOA PS15-1502: Employee of Grant Recipient, Grant recipient. T. Cleveland, CDC FOA PS15-1502: Employee of Grant Recipient, Grant recipient. H. Chancler, CDC FOA PS15-1502: Employee of Grant Recipient, Grant recipient. J. Schneider, CDC FOA PS15-1502: Grant Investigator, Grant recipient. CDC FOA PS17-1704: Grant Investigator, Grant recipient. Chicago Department of Public Health A2 HIV Prevention and Testing Grant: Grant Investigator, Grant recipient.